U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C26H26F3NO3
Molecular Weight 457.4847
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ETRASIMOD

SMILES

OC(=O)C[C@H]1CCC2=C1NC3=CC=C(OCC4=CC(=C(C=C4)C5CCCC5)C(F)(F)F)C=C23

InChI

InChIKey=MVGWUTBTXDYMND-QGZVFWFLSA-N
InChI=1S/C26H26F3NO3/c27-26(28,29)22-11-15(5-8-19(22)16-3-1-2-4-16)14-33-18-7-10-23-21(13-18)20-9-6-17(12-24(31)32)25(20)30-23/h5,7-8,10-11,13,16-17,30H,1-4,6,9,12,14H2,(H,31,32)/t17-/m1/s1

HIDE SMILES / InChI

Molecular Formula C26H26F3NO3
Molecular Weight 457.4847
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

APD-334 (Etrasimod) was discovered as part of our internal effort to identify potent, centrally available, functional antagonists of the S1P1 receptor for use as next generation therapeutics for treating multiple sclerosis (MS) and other autoimmune diseases. APD334 is a potent functional antagonist of S1P1 and has a favorable PK/PD profile, producing robust lymphocyte lowering at relatively low plasma concentrations in several preclinical species. This new agent was efficacious in a mouse experimental autoimmune encephalomyelitis (EAE) model of MS and a rat collagen induced arthritis (CIA) model and was found to have appreciable central exposure. APD-334 has therapeutic potential in immune and inflammatory-mediated diseases such as ulcerative colitis, Crohn’s disease, and atopic dermatitis.

Approval Year

Targets

Targets

PubMed

PubMed

TitleDatePubMed
Discovery of APD334: Design of a Clinical Stage Functional Antagonist of the Sphingosine-1-phosphate-1 Receptor.
2014 Dec 11
Will novel oral formulations change the management of inflammatory bowel disease?
2016 Jun
Modulation of sphingosine-1-phosphate in inflammatory bowel disease.
2017 May
Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists.
2019
Interfering with leukocyte trafficking in Crohn's disease.
2019 Feb-Apr
Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts.
2019 Jan 10
The Selective Sphingosine 1-Phosphate Receptor Modulator Etrasimod Regulates Lymphocyte Trafficking and Alleviates Experimental Colitis.
2019 Jun

Sample Use Guides

Ulcerative Colitis: APD-334 (Etrasimod) 2 mg tablet by mouth, once daily up to approximately 5 years
Route of Administration: Oral
Etrasimod (APD-334) is a potent, selective and orally available antagonist of the sphingosine-1-phosphate-1 (S1P1) receptor with an IC50 value of 1.88 nM in CHO cells.
Substance Class Chemical
Created
by admin
on Sat Dec 16 10:14:25 GMT 2023
Edited
by admin
on Sat Dec 16 10:14:25 GMT 2023
Record UNII
6WH8495MMH
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ETRASIMOD
INN   USAN  
USAN   INN  
Official Name English
(R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA(B)INDOL-3-YL) ACETIC ACID
Systematic Name English
APD334
Code English
ETRASIMOD [USAN]
Common Name English
APD-334(FREE ACID)
Code English
Etrasimod [WHO-DD]
Common Name English
CYCLOPENT(B)INDOLE-3-ACETIC ACID, 7-((4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)PHENYL)METHOXY)-1,2,3,4-TETRAHYDRO-, (3R)-
Systematic Name English
APD-334
Code English
[(3R)-7-{[4-Cyclopentyl-3-(trifluoromethyl)phenyl]methoxy}-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid
Systematic Name English
etrasimod [INN]
Common Name English
Code System Code Type Description
DRUG BANK
DB14766
Created by admin on Sat Dec 16 10:14:25 GMT 2023 , Edited by admin on Sat Dec 16 10:14:25 GMT 2023
PRIMARY
FDA UNII
6WH8495MMH
Created by admin on Sat Dec 16 10:14:25 GMT 2023 , Edited by admin on Sat Dec 16 10:14:25 GMT 2023
PRIMARY
DAILYMED
6WH8495MMH
Created by admin on Sat Dec 16 10:14:25 GMT 2023 , Edited by admin on Sat Dec 16 10:14:25 GMT 2023
PRIMARY
CAS
1206123-37-6
Created by admin on Sat Dec 16 10:14:25 GMT 2023 , Edited by admin on Sat Dec 16 10:14:25 GMT 2023
PRIMARY
NCI_THESAURUS
C166965
Created by admin on Sat Dec 16 10:14:25 GMT 2023 , Edited by admin on Sat Dec 16 10:14:25 GMT 2023
PRIMARY
SMS_ID
100000171846
Created by admin on Sat Dec 16 10:14:25 GMT 2023 , Edited by admin on Sat Dec 16 10:14:25 GMT 2023
PRIMARY
PUBCHEM
44623998
Created by admin on Sat Dec 16 10:14:25 GMT 2023 , Edited by admin on Sat Dec 16 10:14:25 GMT 2023
PRIMARY
USAN
CD-137
Created by admin on Sat Dec 16 10:14:25 GMT 2023 , Edited by admin on Sat Dec 16 10:14:25 GMT 2023
PRIMARY
INN
10435
Created by admin on Sat Dec 16 10:14:25 GMT 2023 , Edited by admin on Sat Dec 16 10:14:25 GMT 2023
PRIMARY
ChEMBL
CHEMBL3544938
Created by admin on Sat Dec 16 10:14:25 GMT 2023 , Edited by admin on Sat Dec 16 10:14:25 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> AGONIST
EC50
TARGET->PARTIAL AGONIST
Relative efficacY of 63% of S1P1 activity 73%
EC50
EXCRETED UNCHANGED
FECAL
SALT/SOLVATE -> PARENT
TARGET->PARTIAL AGONIST
Relative efficacY of 63% of S1P1 activity
EC50
Related Record Type Details
METABOLITE -> PARENT
MINOR
FECAL; PLASMA; URINE
PARENT -> METABOLITE
FECAL
METABOLITE -> PARENT
Related Record Type Details
ACTIVE MOIETY
APD-334 is an orally available S1P1 receptor modulator, discovered by Arena internally. The company believes that APD-334 has therapeutic potential in autoimmune diseases such as ulcerative colitis. Arena states that S1P1 receptors have been demonstrated to be involved in the modulation of several biological responses, including lymphocyte trafficking from lymph nodes to the peripheral blood. By isolating subpopulations of lymphocytes in lymph nodes, fewer immune cells are available in the circulating blood to effect tissue damage.